Jasper Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|
Revenue | $0 | $0 | $2,052 |
Gross Profit | -299 | -288 | 1,769 |
EBITDA | -15,694 | -14,784 | -17,442 |
EBIT | -15,993 | -15,072 | -17,725 |
Net Income | -14,583 | -13,728 | -16,581 |
Net Change In Cash | 0 | 0 | 2,052 |
Free Cash Flow | -11,837 | -15,761 | -16,709 |
Cash | 106,819 | 118,475 | 86,887 |
Basic Shares | 14,986 | 13,334 | 11,044 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1,108 | -1,310 | -566 | -21 |
EBITDA | -64,985 | -38,210 | -31,166 | -31,946 |
EBIT | -66,093 | -39,520 | -31,732 | -31,967 |
Net Income | -64,465 | -24,174 | -23,984 | -31,669 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -442 | |||
Free Cash Flow | -52,334 | -46,434 | -36,106 | -18,267 |
Cash | 86,887 | 38,250 | 84,701 | 19,838 |
Basic Shares | 10,439 | 3,648 | 1,139 | 277 |
Earnings Calls
| Quarter | EPS |
|---|---|
2021-06-30 | -$0.68 |
2021-03-31 | -$0.82 |
2020-12-31 | -$0.99 |
2020-06-30 | -$6.14 |
